Subclinical diabetic cardiomyopathy (DCM) is frequent in asymptomatic subjects with type 2 diabetes (T2DM). We sought the response of functional and fibrosis markers to therapy in a trial of aldosterone antagonism for treatment of DCM.
Introduction
Increasing evidence supports the prevalence of myocardial dysfunction even in asymptomatic type 2 diabetes mellitus (T2DM). 1 -3 This subclinical diabetic cardiomyopathy (DCM) is defined as diastolic or systolic myocardial disease in otherwise healthy, asymptomatic subjects with diabetes that cannot be ascribed to hypertension (HT), coronary artery disease, or other known cardiac disease. 4 The aetiology of DCM is likely multifactorial, 5 but myocardial fibrosis is thought to be a final common pathway in the ensuing myocardial dysfunction. 6 -8 Important drivers of this process in T2DM
include collagen cross-linking via accumulation of advanced glycation end-products (AGE), 9 activation of inflammatory cytokines 10 and potentiation of neurohormonal cascades. 11 Previous work in populations where myocardial fibrosis is a central factor (including dilated cardiomyopathy, 12 ischaemic cardiomyopathy, 13 hypertrophic cardiomyopathy, 14 and hypertensive heart disease 7 ) has shown upregulation of the renin-angiotensin -aldosterone system (RAAS) 15 and resultant aldosterone excess being associated with poor heart failure outcomes including mortality. 16, 17 Aldosterone antagonism in this setting leads to reverse remodelling and improved myocardial function 18 as well as outcomes. 19 The favourable effects have been documented in both systolic 20 and diastolic heart failure. 21, 22 Identification of underlying diffuse myocardial fibrosis by noninvasive means would enable timely identification of those with subclinical DCM and also enable the monitoring of response in myocardial structure and function to anti-fibrotic therapy such as aldosterone antagonism. Echocardiographic calibrated integrated backscatter (cIB) and T1 mapping using cardiac magnetic resonance imaging (CMR) are surrogate markers of tissue characterization, which demonstrate linear relationships with collagen volume fraction (CVF) on endomyocardial biopsy. 23, 24 A number of studies have documented the ability of cIB to track treatment responses during anti-fibrotic therapy. 21, 25 The use of pro-collagen biomarkers is justified by a graded association between biomarker levels in peripheral and coronary sinus blood and myocardial collagen content on biopsy. 26 They have been previously correlated with both CVF on endomyocardial biopsy 26 -28 and myocardial dysfunction on echocardiographic parameters. 29 -31 The evidence of their utility to track the response to therapy is sparse. The purpose of this study was to use fibrotic markers to assess the effect of aldosterone antagonism on myocardial structure and function in DCM. Our hypothesis was that an improvement in diastolic function would be matched by changes in cIB, T1 values, and procollagen markers.
Methods

Subject recruitment
Two hundred and twenty-five apparently healthy subjects with T2DM (121 men, 60 + 9 years) were consecutively recruited from the hospital clinic and community, based on an a priori protocol and independent of indications for echocardiographic exam. All subjects were screened for the presence of diastolic dysfunction. Candidates were excluded if they were pregnant, had a self-reported history of symptomatic micro-or macrovascular complications of diabetes (including nephropathy, neuropathy, retinopathy, peripheral vascular disease, ischaemic heart disease, and stroke) or other significant comorbidities including malignancy, renal failure, or significant psychiatric illness. Absence of valvular, congenital, hypertensive, or ischaemic heart disease was confirmed echocardiographically. Approval for this study was granted by the Human Research Ethics Committees of Princess Alexandra Hospital and The University of Queensland, Brisbane, Australia. All subjects gave written, informed consent to participate in the study and research was carried out in accordance with the Declaration of Helsinki (2008) of the World Medical Association.
Trial design
Eligible subjects with evidence of diastolic dysfunction manifesting as prolonged relaxation on resting echocardiogram [septal diastolic tissue velocity (e m ) . 1 SD below the normal for age-based on previous . This definition of diastolic dysfunction was selected to specifically target those subjects with early subclinical myocardial dysfunction who might be more amenable to reversal of fibrosis with aldosterone antagonism. e m was selected as a reliable and reproducible measure of diastolic function in our laboratory, based upon previously documented intra-and inter-observer test -retest variability. 5 This was particularly important, given the need to accurately assess potentially small treatment effects of spironolactone therapy. Reporting of this clinical trial was performed according to the CONSORT Statement.
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A computerized, block randomization program allocated subjects consecutively to receive 6 months of 25 mg/d spironolactone drug therapy or placebo, in addition to their usual therapy. This dose was selected based upon previous work demonstrating a significant impact on myocardial properties, including diastolic function, in hypertensive 21 and metabolic syndrome 25 populations. Study investigators (C.L.J. and J.W.S.) enrolled subjects and entered computer program data but were blinded to all aspects of randomization including six-subject block sequencing. An independent clinical trials pharmacist assigned and dispensed trial medications (according to the computer generated drug allocation sequence) to facilitate concealment of drug therapy allocation from all participants and researchers in a double-blinded fashion. During the 6 months of follow-up, subjects were specifically reassessed at 1 month and 3 months post-drug commencement with clinical evaluation via telephone call and laboratory appraisal with serum electrolytes (including potassium).
All subjects underwent rigorous analysis of clinical variables, metabolic data, pre-and post-exercise myocardial function, exercise capacity, and pro-collagen biomarkers during the baseline screening phase. The same protocol was repeated in the randomized subjects after 6 months of intervention. This included the following.
Demographic, anthropometric, and metabolic data
Clinical data were collected regarding subject age, sex, and basic anthropometry [to establish body mass index (BMI) and waist-to-hip circumference ratio] and duration of T2DM. Serum glucose, insulin, HbA1c, creatinine, and lipid profile were obtained prior to exercise after fasting for at least 8 h and before administration of hypoglycaemic agents. Insulin resistance was determined by the homeostasis model assessment (HOMA:IR) method. 34 Microalbuminuria, a marker of microvascular disease, was quantified via a random urinary albumin to creatinine ratio and defined as ≥2.5 g/mol (male) and ≥3.5 g/mol (female).
Pro-collagen biomarkers
Pre-exercise peripheral venous blood samples were drawn into ethylenediaminetetraacetic acid and serum specific tubes before being centrifuged (10 min at 48C) and then separated into aliquots for storage at 2808C. Simultaneous analysis of samples was later performed with standard commercially available kits according to the manufacturers' instructions. Amino-terminal propeptides of pro-collagen type I (PINP) and pro-collagen type III (PIIINP) were measured in serum by radioimmunoassay (Orion Diagnostica, Espoo, Finland). The carboxy-terminal propeptide of pro-collagen type I (PICP) was measured in plasma by enzyme-linked immunosorbent assay (Takara Biochemicals Co, Japan). The assay ranges were: 5 -250 mg/L for PINP, 1 -50 mg/L for PIIINP, and 10 -640 ng/mL for PICP. Urine samples were collected pre-exercise and stored at 2808C for later simultaneous analysis of transforming growth factor beta-1 (TGF-b1) by enzyme-linked immunosorbent Spironolactone in diabetic cardiomyopathy assay (RayBiotech, Inc., Norcross, GA, USA) which has a minimum detectable dose of TGF-b1 of ,0.08 ng/mL. All assays were run in duplicate with mean values used for analysis.
Echocardiography
Resting and exercise stress echocardiography (ESE) was performed using a commercially available cardiac ultrasound machine (Vivid 7 General Electric Medical Systems, Milwaukee, WI, USA). Acquisitions were individually optimized for depth, gain, and frame rate to maximize image quality and minimize inconsistency in acoustic windows prior to study comparison and analysis. Standard M-mode and 2D imaging was undertaken at rest. In addition, a colour tissue Doppler overlay was captured on parasternal and apical long-axis images for offline measurement of tissue velocity and strain parameters. Subjects underwent maximal treadmill exercise using the Bruce protocol before being re-imaged in the same parasternal and apical planes. Images were saved in raw data format for offline analysis.
Hemodynamic data and exercise capacity
Vasoactive medications including b-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and nitrates were withheld for at least 12 h before ESE. Hemodynamic parameters including heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were measured pre-, during, and post-ESE. HT was defined as a resting blood pressure of .140/90 mmHg or a normotensive subject on one or more regular antihypertensive medications. Tonometric pulse wave velocity (SphygmoCor; AtCor Medical, Sydney, Australia) between carotid and femoral sites was used to determine aortic stiffness. Cardiorespiratory fitness was assessed by indirect calorimetry (Vmax29c, SensorMedics, Yorba Linda, CA, USA), which measured maximal oxygen consumption [VO 2max (mL/kg/min)] via a closed circuit breathing system during the maximal treadmill exercise test. Exercise capacity was also estimated in metabolic equivalents (METS) based on the duration of treadmill exercise achieved using the standard equation:
Echocardiographic data analysis
Offline analysis was performed to assess left ventricular (LV) wall thickness, valvular morphology, and chamber volumes. Ischaemia was excluded based on the absence of inducible wall motion abnormalities on a standard 16 segment model at peak stress. Significant (.mild) LV hypertrophy was defined as evidence of hypertensive heart disease. The modified Simpson's biplane method was used to measure LV ejection fraction at rest and peak exercise. Conventional apical views (fourchamber, two-chamber, and long axis) in colour tissue Doppler imaging (TDI) formats at rest and peak were used to obtain tissue velocity, strain, and strain rate curves from the six basal segments with standard commercial software (Echopac; GE Vingmed, Horten, Norway). Peak systolic tissue velocity (s m ), peak e m , and peak late diastolic tissue velocity (a m ) were calculated from tissue velocity curves by placing a sample volume at the level of the mitral annulus. An average value from three consecutive tissue velocity curves was established for each of the six basal segments. The resultant values for the six segments were then averaged to determine mean basal longitudinal e m , a m , and s m . Pulse wave tissue Doppler was also performed to establish e m by placing a sample volume at the septal and lateral aspects of the mitral annulus. This septal e m value was used, together with the peak early transmitral velocity (E), to establish the E/e m ratio as a measure of filling pressures. 35 TDI strain and strain rate curves were derived from the same apical views by placing sample volumes in the mid-myocardium of the six basal segments and tracking the position of the sample volume throughout the cardiac cycle. An average peak value from three consecutive curves was used to calculate both strain and systolic strain rate. In all cases, the angle of incidence between the transducer and the wall of interest was maintained ,208.
cIB calculation was performed from raw data using images exported in native format. Regions of interest were placed over parallel sub-segments of the pericardium, posterior wall, and anteroseptum in a standard parasternal long-axis view (Echopac, GE Vingmed). Mean pericardial IB intensity at end-diastole was subtracted from mean IB intensity of the posterior wall and the anteroseptum which were then averaged to establish mean cIB. Reproducibility of this technique has been previously verified 5 and all cIB measurements of signal intensity were performed at end-diastole by the same observer (C.L.J.). LV mass was indexed (LVMI) for height using a previously validated method.
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Cardiac magnetic resonance imaging A 1.5 T scanner (Signa HDxT General Electric Healthcare; Milwaukee, WI) was used with VCG gating, an 8-channel cardiac surface coil, and inspiratory breath holds. LV ejection fraction was assessed by a standard steady state free precession pulse sequence. As previously described,
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T1 mapping was performed in three standard short axis slices (basal, midcavity, and apical) with a prototype modified Look-Locker FIESTA technique using saturation recovery imaging. Each slice yielded eight images with consecutively longer inversion times, upon which a curve-fitting technique was used to generate a T1 map. Gadobenate dimeglumine (0.1 mmol/kg) was then administered, with delayed hyperenhancement imaging and post-contrast T1 mapping performed 8 and 12 min later, respectively. Prototype Vizpack software (General Electric Healthcare) was used to analyse the T1 maps in 16 segments. 37 Exponential recovery curves of signal intensity were then created to extrapolate the T1 time for each segment. Segments were visually graded as good, acceptable, and poor-the latter were excluded from analysis. Segmental post-contrast T1 values were averaged to determine the mean myocardial T1. Potential covariates (heart rate, weight, renal function, and contrast dose) were screened as predictors of post-contrast T1 values using univariate linear regression. Correction of T1 values for established covariates was performed prior to data analysis. Myocardial extra-cellular volume (ECV) was derived from the reciprocals of myocardial and blood preand post-contrast T1 values and haematocrit using a previously defined equation. 38 
Statistical analysis
Results are expressed as mean + SD for continuous, normally distributed variables, median and interquartile ranges (IQR) for continuous, and non-normally distributed variables and percentages for categorical variables. The normal distribution of continuous variables was verified using a Kolmogorov -Smirnov test. Analysis of normally distributed continuous variables was performed with Pearson bivariate correlations. Multivariate linear regression modelling of univariate correlates was performed to determine independent associations. Candidate variables for the models were selected from unadjusted correlates that were significant at P , 0.05 and did not express co-linearity. Comparison between spironolactone and placebo groups pre-and post-intervention was achieved using analysis of variance (ANOVA) for parametric continuous variables, the Wilcoxon test for nonparametric continuous variables and X 2 for categorical variables. Statistical analysis was performed using C.L. Jellis et al.
standard statistical computer software (SPSS 17, SPSS Inc., Chicago, IL, USA). A P value of ,0.05 was deemed to be statistically significant.
Sample size
The study was powered to demonstrate a difference in e m between the intervention groups after 6 months drug therapy. Power calculations were based on previous work in our group which has shown a significant impact on myocardial properties with spironolactone in hypertensive heart disease in 30 patients 21 and a prevalence of DCM in asymptomatic subjects with T2DM of 27%. 1 Therefore, assuming a power of 0.8, a error of 0.05, and selected effect size of 1.0, we estimated a proportionate reduction should be detectable from a total drug intervention population of 34 subjects. To allow for drop-out, 225 subjects were recruited on the assumption that this would provide 75 eligible subjects with diastolic dysfunction of whom 50 would agree to randomization to the drug intervention. There were no interventional studies in T2DM with T1 mapping or pro-collagen biomarkers on which this study could be powered. Previous work correlated T1 values with biopsy evidence of fibrosis in 45 patients. 24 Results
Patient characteristics
Screening of 225 subjects was undertaken between February 2009 and January 2011. Of the 83 subjects with myocardial dysfunction, 2 were excluded after ESE suggested occult coronary artery disease. Of the 81 remaining subjects with diastolic dysfunction, 49 agreed to participate in the pharmacological intervention with 24 being randomized to spironolactone (25 mg/day) and 25 to placebo ( Figure 1) . CMR data were unavailable in 7 patients who declined protocol or prematurely aborted the scan with claustrophobia. No significant differences in demographics, anthropometry, or biochemistry were observed between the intervention participants (n ¼ 49) and those who declined or were excluded from participation (n ¼ 34, 56% males, age 58 + 10 years, mean septal e m 24.1 + 0.7). Non-participants had similar echo and biomarker parameters, apart from lower LVEF (55 + 22 vs. 65 + 6%) and a thinner anteroseptum (0.9 + 0.4 cm vs. 1.0 + 0.2 cm). Mean duration of drug therapy was 6 + 1 months in both groups (P ¼ 0.106). Premature discontinuation of therapy occurred in two subjects, both on placebo. This was attributed to dry mouth after 12 weeks in one subject and diarrhoea after 3 weeks in the other. However, all randomized subjects (including those who prematurely ceased therapy) returned for post-intervention re-assessment. All subjects were analyzed according to original assigned group.
Pre-intervention
Baseline clinical features of the two groups pre-randomization were similar with respect to age, sex distribution, anthropometry, duration of diabetes, hemodynamic parameters, exercise capacity, pro-collagen biomarkers, T1 values, ECV, and biochemical markers including glycemic and lipid control ( Table 1) . Antihypertensive use was similar between groups with no difference with respect to individual or combined total number of vasoactive medications. No subjects were on aldosterone antagonists in either group preintervention. Resting and stress myocardial function (diastolic and systolic), deformation parameters including strain and strain rate (SR) (diastolic and systolic) and cIB were well matched between groups. A clinically insignificant, although statistically significant, difference was noted in the E wave and E/A ratio between groups. However, both groups demonstrated a ratio ,1.0 supportive of the other diastolic parameters which reflected prolonged relaxation in both groups to a similar degree. Despite this resting diastolic dysfunction, resting systolic deformation parameters and myocardial exercise response were noted to be relatively preserved and similar in both groups pre-intervention. (Table 2) Post-intervention After 6 months of intervention, both groups maintained similar anthropometric, biochemical, and hemodynamic profiles to each Spironolactone in diabetic cardiomyopathy other and to baseline. Low dose spironolactone had no beneficial effect on blood pressure, arterial stiffness, or LV mass. There was also no difference in adverse effects between the two groups. In particular, no male subjects developed gynaecomastia and neither serum potassium nor renal function deteriorated in the spironolactone group. (Table 3) Myocardial function A statistically significant improvement was not observed in either e m or E/e m with treatment. Significant differences were identified in the change in resting mitral inflow profile (DE wave and DE/A ratio) between the treatment and placebo groups. ( 
Myocardial structure
The changes in diastolic function were complimented by an improvement in cIB readings post-intervention, with subjects on spironolactone demonstrating a significant reduction in myocardial signal intensity according to cIB values ( 
036). T1 values and
ECVwere similar between groups at baseline ( Table 1 ) and postintervention ( Table 3) . Both DT1 values and DECV failed to correlate with changes in biochemical, echocardiographic, or biomarker variables with intervention.
Pro-collagen biomarkers
All pro-collagen biomarkers levels were well matched between the two intervention groups before commencement of therapy ( Table 1) . Pre-and post-intervention values were within the detection limits of the different assays. After 6 months of intervention, there were no appreciable changes in any of the pro-collagen biomarkers between the treatment groups ( Table 3) . On bivariate analysis of biomarker values with intervention across the entire study population, several relatively weak associations were noted which did not appear of clinical relevance. Specifically, DPINP was related to Dhip circumference (r ¼ 0.318, P ¼ 0.029), Dtriglycerides (r ¼ 0.363, P ¼ 0.012), and DE/e m (r ¼ 0.386, P ¼ 0.006), of which DE/e m was independently associated with DPINP (b ¼ 0.454, P ¼ 0.002) using multivariate linear regression. DPICP was independently associated with both Dstrain (b ¼ 20.275, P ¼ 0.048) and Dalbumin (b ¼ 20.286, P ¼ 0.040). DPIIINP and DTGF-b1 were not associated with any alterations in biochemical, functional, or structural parameters with intervention.
Discussion
The results of this randomized, placebo-controlled trial suggest aldosterone blockade to be associated with minor changes in diastolic function in DCM, matched by an improvement of myocardial tissue characterization (cIB), but not systolic function, biomarker levels, or T1 values. This challenges a long-held assumption that myocardial fibrosis causes the functional disturbance observed in non-ischaemic diabetic heart disease. Our largely negative results provide a rationale for exploring other potential causes of this myocardial dysfunction in T2DM. Although our numbers were relatively small, our target sample size was achieved and there were no ambiguous trends or borderline values to infer that statistical significance would have been achieved with a larger study sample. 
Spironolactone in diabetic cardiomyopathy
These findings are less than those achieved with spironolactone in hypertensive heart disease 21 and the metabolic syndrome. 25 Although previously described populations did contain a proportion of subjects with T2DM, the duration and control of T2DM was not documented and the T2DM sub-group data was not published for direct comparison. 25 Their subjects may have had more advanced disease and underling myocardial fibrosis given their higher PIIINP, increased cIB and lower strain results at baseline even despite greater RAAS blockade pre-intervention. 25 The discordance of our findings suggests that fibrosis may be less integral to the process of early, subclinical DCM.
Myocardial dysfunction
Diastolic dysfunction is a common feature of early DCM, although symptoms of fatigue, dyspnoea and reduced exercise capacity are non-specific, and often attributed to obesity and deconditioning. Impaired myocardial relaxation has been postulated to be a consequence of increased myocardial stiffness due to factors such as fibrosis, 39 cardiomyocyte hypertrophy, 40 microvascular disease, 41 AGE accumulation, and receptor of AGE expression. 42 In this study, we found only a subtle beneficial effect of treatment on diastolic function, albeit assessed as diastolic class (peak E wave velocity and E/A ratio) rather than diastolic tissue velocity. e m was a useful, single, ageadjusted measure for initial identification and stratification of subjects with DCM. Its failure to change significantly with treatment may reflect persistent prolonged relaxation consistent with unmodified myocardial fibrosis or technical aspects 43 that contribute to its test-retest variation in apparently stable, healthy subjects. 44 However, it is a less load dependent measure than the mitral inflow pattern, including the E/A ratio, and therefore we felt it would be a more reliable and reproducible continuous measure of diastolic function for detection of potentially small treatment effects. Septal e m was preferentially selected due to the availability of age-based normal values 32 and better correlation with invasive pressures 45 at the time of study design. Left atrial volume index may have provided some additional information regarding filling pressures, but it may be influenced by a 'legacy' effect of previously raised filling pressure, such that it may not reflect the hemodynamic conditions at the time of the study. The discrepancy between parameters of diastolic function may be explained by the diuretic properties of spironolactone acting to reduce left heart filling pressures, changes in LV preload or afterload or by variable grades of reproducibility between measures. This may alter the E/A ratio without truly affecting myocardial diastolic relaxation as measured by e m or the E/e m ratio which remained unchanged despite spironolactone therapy. (Table 3 ) Alternatively, a trend towards higher baseline E/e m was noted in the spironolactone treated group. Although not statistically significant, a preintervention increase of filling pressures could theoretically have resulted in regression towards the mean being an alternative explanation for the change in diastolic parameters rather than a true effect of spironolactone. Conversely, as neither group had a clearly abnormal baseline E/e m ratio, treatment effect of spironolactone may be more difficult to appreciate. Inconsistency between measures of diastolic function may also reflect that not all parameters measure the same phenomenon at the same time within the cardiac cycle. Diastole is hallmarked by active early relaxation and late passive compliance but interaction between these phases may be disease specific. Recent advances in our understanding of LV intraventricular vortices also show promise in conceptualization of diastolic filling, but require ongoing investigation. 46 
Myocardial structure
The cIB response in this study suggests an effect of spironolactone on myocardial structure. These results are concordant with previous work showing improvement in cIB values with spironolactone therapy in a hypertensive population with diastolic dysfunction, 21 a cohort with systolic heart failure 47 and a group with the metabolic syndrome 25 but has not been previously explored in T2DM. Our results suggest that it may have some beneficial role in LV reverse remodelling in DCM when prescribed in addition to standard medical therapy. Although interstitial fibrosis may be responsible for these myocardial alterations, this cannot be further determined with cIB given its reliance on relatively non-specific indicators of signal intensity and variability-the physiological coefficient of variability was 29% for placebo and 21% for spironolactone. In contrast, pro-collagen propeptide levels were not altered after anti-fibrotic therapy in DCM. Most of the previous work demonstrating improvement in pro-collagen biomarkers with anti-fibrotic therapeutics has been restricted to hypertensive heart disease 48, 49 (where biomarkers concomitantly reduce with CVF after antihypertensive therapy) and congestive heart failure secondary to LV systolic dysfunction. 50, 51 The RALES sub-study work of Zannad et al. 51 specifically investigated the treatment effect of spironolactone therapy. Not only were they able to demonstrate a reduction in biomarker levels with spironolactone, but those with higher baseline biomarker levels were also found to have a spironolactone-related morbidity and mortality benefit. However, there are several important distinctions between their retrospective study and ours which may explain the disparity in our findings. Their subjects had severe, symptomatic systolic heart failure with a mean ejection fraction of only 26% and a majority of subjects with NYHA Class III or IV heart failure. Their mean biomarker levels were higher pre-and post-intervention and over 90% of their subjects were medicated with ACE inhibitors at the time of randomization. In contrast, our subjects may have been simply too well or too early in the disease process to demonstrate a detectable alteration in propeptide levels with a similar spironolactone therapeutic regimen. Although the adequacy of spironolactone dose could be questioned, the effectiveness of 25 mg per day on collagen turnover and myocardial function has been previously demonstrated in both subclinical metabolic disease, 25 and HT. 21 The conflicting results of cIB, T1 mapping, and pro-collagen biomarkers with diastolic function data have several plausible causes. However, the disparity suggests that the argument for underlying myocardial fibrosis as the primary cause of DCM is weaker than initially postulated. Technical limitations of the cIB method may contribute to this lack of concordance, even despite the methodological caveats implemented to minimize subjectivity. As can be seen when tracking cIB throughout the cardiac cycle, there is considerable cyclic variation in signal intensity related to deformational changes. Hence, an alteration in myocardial function may result in an apparent change in signal intensity and cIB. This may be more pronounced in subjects with preserved systolic function such as ours, compared with those with significant LV impairment who were originally used to validate cIB against biopsy for measurement of fibrosis. 23 While a relationship was noted between DcIB and Da m , there was no correlation between DcIB and the change in other parameters (such as strain) with therapy to add weight to this argument. Alternatively, the difference between the observed effects of spironolactone on cIB and pro-collagen biomarkers may be explained by a pathological process, other than myocardial fibrosis, underlying DCM. This could lead to alteration in myocardial function and signal intensity (cIB) without affecting collagen turnover. The role of intramyocardial fat in obese subjects such as these in unknown and may also impact upon myocardial backscatter and diastolic function, whilst negating the effect of anti-fibrotic therapy. However, a recent study of spironolactone in an obese population still demonstrated efficacy. 25 Previous work has suggested that cardiomyocyte hypertrophy, 40 perivascular fibrosis, 52 and arteriolar hyalinization 53 may have more important roles than cardiomyocyte fibrosis in the underlying pathophysiology of DCM. Aldosterone antagonism may still have a relevant therapeutic role in these processes but requires further assessment. T1 values may have lacked adequate sensitivity to detect a treatment effect, particularly given the early disease stage. Associations of T1 values with myocardial collagen content have previously been demonstrated in a more heterogeneous cohort with advanced disease (at least NYHA Class II heart failure). 24 The myocardial ECV results of our participants are slightly higher than those reported in patients without diabetes but lower than those with cardiac amyloidosis and myocardial infarction. 54 This may reflect a true pathological manifestation of diabetes, although differences in T1 sequences and method of contrast administration (bolus or infusion) between studies may confound results. The recently demonstrated relationship between age and ECV 55 was not replicated in our study.
Limitations
The main limitation of this trial is the employment of non-invasive techniques to detect underlying myocardial fibrosis. While confirmatory histological evidence of fibrosis would further validate our findings, myocardial biopsy is an invasive procedure which carries a significant degree of risk and cost, and could therefore not be ethically justified in an asymptomatic population such as ours. Technical issues related to the use of cIB are highlighted above. Employment of procollagen biomarkers and T1 mapping may also be problematic in early DCM due to limitations in technique sensitivity, resulting in mild disease being inadequately detected at baseline or with monitoring after spironolactone therapy. The use of ESE does not completely exclude macrovascular ischaemic heart disease. However, our centre has both high sensitivity and specificity in stress imaging interpretation, 56 making it unlikely that hemodynamically significant coronary lesions were underappreciated. Invasive coronary angiography of this asymptomatic population could also not be justified on ethical grounds. This trial is limited by its relatively small subject numbers and findings need to be replicated in a larger cohort before they can be generalized to the wider population with T2DM and DCM. Prevalence of subclinical DCM was higher than required by our power calculations, although lower than a similar study cohort. 3 Hence, there remains the possibility that an association between non-invasive measures of fibrosis or a treatment effect of spironolactone were unappreciated. Some of the weak clinical correlations observed may be strengthened in a larger subject group.
Conclusions
The increasing incidence and prevalence of T2DM and the metabolic syndrome are likely to lead to a further increment in the frequency of DCM. While strategies to reduce the development of T2DM and preventive approaches based on lifestyle intervention are important and probably effective for controlling DCM, patient adherence is often difficult. The results of this randomized trial indicate that while aldosterone antagonism induces favourable changes in some parameters of diastolic function and myocardial backscatter, the absence of effect on collagen biomarkers and T1 values suggests that the role of myocardial fibrosis in DCM is limited.
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